Previous 10 | Next 10 |
[[ABCB]], [[ASB]], [[BOOM]], [[CE]], [[COF]], [[CSL]], [[EIG]], [[FE]], [[FFBC]], [[FFIN]], [[GBCI]], [[HTH]], [[INTC]], [[NUVB]], [[OZK]], [[RHI]] ,[[RNR]], [[SAM]],[[SIVB]], [[SKX]], [[SNAP]] ,[[TWTR]] ,[[VICR]], [[VRSN]],[[WRB]], [[WSFS]]For Seeking Alpha's full earnings season c...
Nuvation Bio Inc. Class A (NYSE:NUVB) traded at a new 52-week low today of $8.15. Approximately 116,000 shares have changed hands today, as compared to an average 30-day volume of 1 million shares. In the past 52 weeks, Nuvation Bio Inc. Class A share prices are bracketed by a current lo...
Nuvation Bio Inc. Class A (NYSE:NUVB) traded at a new 52-week low today of $8.43. This new low was reached on below average trading volume as 133,000 shares traded hands, while the average 30-day volume is approximately 1.1 million shares. In the past 52 weeks, shares of Nuvation Bio Inc...
David Abrams’ 13F portfolio value increased ~25% this quarter from $3.55B to $4.44B. The number of positions decreased from 17 to 16. Abrams Capital Management added Change Healthcare while dropping TransMedics Group during the quarter. The top three positions are Lithia Mo...
Nuvation Bio Appoints David C. Hanley, Ph.D., as Chief Technical Operations Officer Experienced technical operations and CMC leader brings scientific and strategic expertise in oncology drug development and life cycle management PR Newswire NEW YORK , J...
Shares of Nuvation Bio Inc. Class A (NYSE:NUVB) traded today at $15.23, eclipsing its 52-week high. So far today approximately 164,000 shares have been exchanged, as compared to an average 30-day volume of 443,000 shares. Over the past year, Nuvation Bio Inc. Class A has traded in a rang...
Nuvation Bio to Participate in the Jefferies Virtual Healthcare Conference PR Newswire NEW YORK , May 26, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differen...
Seth Klarman’s 13F portfolio value increased from $10.84B to $12.56B this quarter. Baupost Group increased Alphabet and Intel while reducing Fox Corp and dropping ViacomCBS. They also built small stakes in several SPACs. The portfolio continues to be heavily concentrated wi...
Nuvation Bio (NUVB): Q1 GAAP EPS of -$0.12.Cash, cash equivalents and marketable securities of $824.7MPress Release For further details see: Nuvation Bio reports Q1 results
Nuvation Bio Reports First Quarter 2021 Financial Results and Provides Business Update Ongoing enrollment in Phase 1/2 study of NUV-422 in high-grade gliomas Strong balance sheet with cash, cash equivalents and marketable securities of $824.7million as of March 31, 2021 ...
News, Short Squeeze, Breakout and More Instantly...
Nuvation Bio Inc. Class A Company Name:
NUVB Stock Symbol:
NYSE Market:
Nuvation Bio Inc. Class A Website:
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at t...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced today that David Hung, M.D., Founder, President, and Chief Executive Officer of Nu...
Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at...